08:50 EDT Omeros (OMER) up 124% at $9.20 after entering license agreement for zaltenibert
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Novo Nordisk, Omeros enter asset purchase, license agreement for zaltenibert
- Omeros Corporation Completes Promising Phase 2 Study on OMS906 for PNH
- Promising Clinical Data and Unique Mechanism of Narsoplimab Justify Buy Rating
- Omeros announces publication of narsoplimab survival outcomes in TA-TMA
- Omeros Corporation’s Positive Earnings Call Highlights Progress